Zürcher Nachrichten - Study shows how fast kilos return after ending weight-loss drugs

EUR -
AED 4.240317
AFN 75.613798
ALL 93.083621
AMD 422.304338
AOA 1058.65099
ARS 1729.863941
AUD 1.63662
AWG 2.078049
AZN 1.966429
BAM 1.954423
BBD 2.325762
BDT 142.67949
BHD 0.435489
BIF 3446.098132
BMD 1.154472
BND 1.477659
BOB 13.741379
BRL 5.906976
BSD 1.154687
BTN 109.989518
BWP 15.555907
BYN 3.432982
BYR 22627.646025
BZD 2.322364
CAD 1.609934
CDF 2611.992228
CHF 0.935157
CLF 0.026841
CLP 1056.411264
CNY 7.789916
CNH 7.788897
COP 3623.690519
CRC 524.22617
CUC 1.154472
CUP 30.593501
CVE 110.187856
CZK 24.259377
DJF 205.172641
DKK 7.476145
DOP 67.321992
DZD 153.279508
EGP 57.585512
ERN 17.317076
ETB 186.715352
FJD 2.553114
FKP 0.856331
GBP 0.854713
GEL 3.013068
GGP 0.856331
GHS 13.556568
GIP 0.856331
GMD 84.856485
GNF 10140.856305
GTQ 8.81087
GYD 241.831737
HKD 9.057432
HNL 30.951928
HRK 7.535817
HTG 150.98364
HUF 364.606998
IDR 20526.507465
ILS 3.461279
IMP 0.856331
INR 110.133259
IQD 1512.727812
IRR 1587081.157342
ISK 142.20827
JEP 0.856331
JMD 183.379231
JOD 0.818459
JPY 183.716281
KES 149.365809
KGS 100.958668
KHR 4681.70199
KMF 491.805569
KRW 1637.335322
KWD 0.356743
KYD 0.962318
KZT 538.348431
LAK 26078.516124
LBP 103405.556276
LKR 387.005699
LRD 208.423177
LSL 18.684038
LTL 3.408855
LVL 0.698328
LYD 7.358816
MAD 10.768161
MDL 20.068863
MGA 4945.473339
MKD 61.481956
MMK 2423.870661
MNT 4149.464085
MOP 9.331386
MRU 46.314972
MUR 54.25975
MVR 17.836226
MWK 2002.272162
MXN 19.799721
MYR 4.722482
MZN 73.776479
NAD 18.683957
NGN 1572.009557
NIO 42.490068
NOK 10.961657
NPR 175.981506
NZD 1.962504
OMR 0.443899
PAB 1.154692
PEN 3.900486
PGK 5.105359
PHP 70.2929
PKR 320.577493
PLN 4.303005
PYG 6873.158225
QAR 4.209453
RON 5.242474
RSD 117.329831
RUB 95.245181
RWF 1696.29036
SAR 4.323331
SBD 9.311619
SCR 16.647423
SDG 693.263532
SEK 10.968947
SGD 1.478549
SLE 28.396685
SOS 659.929398
SRD 43.581889
STD 23895.234065
STN 24.482541
SVC 10.103839
SZL 18.680679
THB 38.101605
TJS 10.663842
TMT 4.052196
TND 3.38493
TRY 55.083338
TTD 7.832449
TWD 37.252468
TZS 3059.347785
UAH 51.797563
UGX 4301.007424
USD 1.154472
UYU 46.517634
UZS 13778.234292
VES 872.506333
VND 30195.208254
VUV 137.805149
WST 3.155998
XAF 655.489565
XAG 0.017742
XAU 0.000265
XCD 3.120017
XCG 2.081125
XDR 0.815219
XOF 655.495238
XPF 119.331742
YER 275.226374
ZAR 18.707811
ZMK 10391.663406
ZMW 21.598785
ZWL 371.739428
  • RBGPF

    0.8600

    70.6

    +1.22%

  • NGG

    -1.3400

    79.54

    -1.68%

  • BCC

    -1.7100

    84.89

    -2.01%

  • JRI

    -0.0100

    12.8

    -0.08%

  • GSK

    -0.9900

    51.97

    -1.9%

  • RIO

    0.5500

    101.65

    +0.54%

  • BCE

    -0.2100

    22.54

    -0.93%

  • CMSD

    -0.1000

    21.72

    -0.46%

  • CMSC

    -0.1838

    21.56

    -0.85%

  • RELX

    0.0750

    35.595

    +0.21%

  • RYCEF

    -0.1000

    20.9

    -0.48%

  • BTI

    -2.1700

    57.16

    -3.8%

  • VOD

    -0.4400

    15.75

    -2.79%

  • BP

    1.3000

    42.93

    +3.03%

  • AZN

    0.0300

    161.45

    +0.02%

Study shows how fast kilos return after ending weight-loss drugs
Study shows how fast kilos return after ending weight-loss drugs / Photo: Armend NIMANI - AFP/File

Study shows how fast kilos return after ending weight-loss drugs

When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.

Text size:

But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.

A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.

They have been found to help people lose between 15-20 percent of their body weight.

"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.

However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.

This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.

So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.

Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.

While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.

However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.

The researchers projected that the participants would return to their original weight in 18 months.

Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.

People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.

This meant that people taking the drugs regained their weight four times faster.

- 'Starting point, not a cure' -

"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.

But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.

This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.

Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."

"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.

If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.

"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.

"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.

A.Ferraro--NZN